medroxyprogesterone acetate has been researched along with Cancer of Endometrium in 223 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (1.35) | 18.7374 |
| 1990's | 60 (26.91) | 18.2507 |
| 2000's | 71 (31.84) | 29.6817 |
| 2010's | 66 (29.60) | 24.3611 |
| 2020's | 23 (10.31) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Cui, Y; Li, J; Li, X; Mao, F; Ni, S; Ou, M; Sun, X; Tang, Y; Wang, Y; Wu, H; Zhu, J | 1 |
| Ikeda, Y; Kajiyama, H; Moriyama, Y; Suzuki, S; Tamauchi, S; Yoshikawa, N | 1 |
| Andrisani, A; Buzzaccarini, G; Chiantera, V; Cucinella, G; Etrusco, A; Giampaolino, P; Gullo, G; Laganà, AS; Noventa, M; Perino, A; Tomaiuolo, R; Vitagliano, A | 1 |
| Aoki, D; Banno, K; Chiyoda, T; Hirano, T; Makabe, T; Sakai, K; Takahashi, M; Yamagami, W; Yoshimura, T | 1 |
| Chen, X; Cheng, Y; Hao, M; Lv, Q; Shan, W; Wang, Y; Xie, L; Xu, Z; Yang, B | 1 |
| Buca, D; D'Antonio, F; De Rocco, S; Dessole, M; Fanfani, F; Leombroni, M; Liberati, M; Lucidi, A; Nappi, L; Oronzii, L; Petrillo, M; Scambia, G | 1 |
| Abd Jamil, AH; Chung, I; Mat Adenan, NA; Omar, IS | 1 |
| Gu, W; Kobayashi, T; Mitsuhashi, A; Shozu, M | 1 |
| Chung, I; Godoy, A; Gunasagran, Y; Mat Adenan, NA; Omar, IS; Teo, IH | 1 |
| Ascione, M; Bifulco, G; Boccia, D; Buonfantino, C; Cafasso, V; De Angelis, MC; Della Corte, L; Giampaolino, P; Grasso, G; Gullo, G; Mercorio, A; Palumbo, M; Serafino, P; Verrazzo, P; Viciglione, F | 1 |
| Fukuma, Y; Hamuro, A; Hasegawa, K; Ikenoue, S; Kasuga, Y; Ochiai, D; Oishi, M; Tamai, J; Tanaka, M; Tanaka, Y; Yamagami, W; Yoshimura, T | 1 |
| Hayashi, M; Murakami, H; Ohmichi, M; Terada, S | 1 |
| Hao, Y; Kuang, L; Sun, F; Zhang, B; Zhou, J | 1 |
| Chalapati, W; Cheewakriangkrai, C; Khunamornpong, S; Kietpeerakool, C; Kleebkaow, P; Lumbiganon, P; Rattanakanokchai, S; Rattanalappaiboon, D; Sribanditmongkhol, N; Tangjitgamol, S; Tangsiriwattana, T; Temtanakitpaisan, A; Tiyayon, J | 1 |
| Eguchi, S; Ga, H; Honjoh, H; Miyamoto, Y; Mori, M; Nishijima, A; Osuga, Y; Sone, K; Taguchi, A | 1 |
| de Gregorio, N; Dimpfl, M; Janni, W; Schäffler, H; Schochter, F | 1 |
| Wang, D; Zhang, M; Zhang, Z; Zhou, J | 1 |
| Ramirez, PT; Santía, MC; Vilches, JC | 1 |
| Cao, W; Gao, W; Sun, X; Wang, L; Zheng, P | 1 |
| Fujiwara, T; Hanaoka, H; Hori, M; Kawasaki, Y; Mitsuhashi, A; Shozu, M | 1 |
| Bertozzi, S; Biasioli, A; Cagnacci, A; Londero, AP; Mangino, FP; Mariuzzi, L; Orsaria, M; Scrimin, F | 1 |
| Chung, YS; Kim, S; Kim, SW; Kim, YT; Lee, JY; Nam, EJ; Park, E; Woo, HY | 1 |
| He, Y; Wang, J; Wang, Y; Zhou, R | 1 |
| Cho, A; Kim, DY; Kim, JH; Kim, YM; Kim, YT; Lee, SW; Park, JY; Suh, DS | 1 |
| Fujiwara, Y; Noguchi, E; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Watanabe, R; Yonemori, K; Yoshida, H; Yunokawa, M | 1 |
| Li, RH; Liu, H; Wang, XP | 1 |
| Li, L; Lin, J; Lou, H; Wang, F; Xu, H; Yu, A; Yu, H; Zhang, X | 1 |
| Kajiyama, H; Kikkawa, F; Mizuno, M; Niimi, K; Sakata, J; Shibata, K; Suzuki, S; Tamauchi, S; Utsumi, F | 1 |
| Kanao, H; Kato, K; Matoda, M; Nomura, H; Okamoto, S; Omatsu, K; Sugiyama, Y; Takeshima, N; Tanigawa, T; Utsugi, K | 1 |
| Erdenebaatar, C; Honda, R; Katabuchi, H; Monsur, M; Ohba, T; Saito, F; Tashiro, H; Yamaguchi, M | 1 |
| Chen, Y; Dong, C; Dong, M; Hou, J; Li, L; Mu, N; Qv, L; Wang, Y; Xia, M; Xue, F; Zuo, Y | 1 |
| Aoki, D; Banno, K; Hirasawa, A; Kataoka, F; Makabe, T; Nomura, H; Sakai, K; Susumu, N; Yamagami, W | 1 |
| Biliatis, I; Dursun, P; Halaska, MJ; La Russa, M; Laky, R; Lindquist, D; Polterauer, S; Sukhin, V; Zalewski, K; Zapardiel, I | 1 |
| Cohen, M; Danilack, VA; DiSilvestro, P; Fiascone, S; Kalife, E; Kao, MJ; Lokich, E; Luis, C; Robison, K; Singh, K | 1 |
| Che, X; Jiang, J; Li, W; Liu, Z; Wang, Y; Zhang, L | 1 |
| Liu, FS; Liu, JC; Yang, HC | 1 |
| Bae, DS; Kang, SB; Kim, JW; Kim, MK; Kim, S; Lee, TS; Lim, MC; Nam, JH; Paek, J; Seong, SJ | 1 |
| Hamada, M; Hasegawa, K; Ito, K; Katoh, T; Kozawa, E; Shintani, D; Yano, M; Yasuda, M | 1 |
| Ben-Baruch, G; Faigenbaum, R; Haklai, R; Kloog, Y | 1 |
| Boyd-Rogers, S; Broaddus, RR; Chen, LM; Conrad, P; Cornelison, T; Daniels, MS; Gershenson, DM; Loose, DS; Lu, KH; Lynch, H; Milbourne, A; Munsell, MF; Nogueras-Gonzalez, GM; Rubin, M; Yates, MS | 1 |
| Bae, DS; Kim, DY; Kim, JH; Kim, JW; Kim, TJ; Kim, YM; Kim, YT; Nam, JH; Park, JY | 1 |
| Jun, HS; Kim, MK; Kim, ML; Kim, YS; Lee, YH; Seong, SJ; Song, T; Yoon, BS | 1 |
| Akashi, D; Kato, H; Minobe, S; Okamoto, K; Shimada, C; Todo, Y | 1 |
| Anderson, G; Aragaki, AK; Beresford, SA; Cauley, JA; Chlebowski, RT; Eaton, CB; Gass, M; Howard, BV; Hsia, J; Jackson, RD; Johnson, KC; Kooperberg, C; Kuller, LH; LaCroix, AZ; Lewis, CE; Limacher, M; Liu, S; Manson, JE; Margolis, KL; Martin, LW; O'Sullivan, MJ; Ockene, JK; Powell, LH; Prentice, RL; Rossouw, JE; Simon, MS; Stefanick, ML; Thomson, CA; Van Horn, L; Vitolins, MZ; Wactawski-Wende, J; Wallace, RB; Wassertheil-Smoller, S | 1 |
| Cade, TJ; Neesham, D; Quinn, MA; Rome, RM | 2 |
| Li, XP; Liu, BJ; Wang, JL; Wei, LH; Zhao, LJ | 1 |
| Clarke, BA; Feigenberg, T; Ferguson, SE; Gien, LT; Ismiil, N; Laframboise, S; Massey, C; Simpson, AN | 1 |
| Iwasaku, K; Kataoka, H; Kitawaki, J; Kuroboshi, H; Mori, T; Sawada, M; Tatsumi, H; Yamamoto, T | 1 |
| Chao, HT; Chao, KC; Lee, FK; Lee, WL; Ng, HT; Wang, PH; Yen, MS; Yuan, CC | 1 |
| Ankarali, H; Caglar, M; Mesci-Haftaci, S; Yavuzcan, A | 1 |
| Aki, I; Fujita, M; Kimura, T; Kobayashi, E; Mabuchi, S; Ohyagi-Hara, C; Sawada, K; Tsutsui, T; Ueda, Y; Yoshino, K | 1 |
| Aldossary, M; Arendas, K; Cipolla, A; Leader, A; Leyland, NA | 1 |
| Brady, WE; Duska, LR; Fischer, EG; Horowitz, NS; Ivanovic, M; Leslie, K; Mannel, RS; Todd, W; Walker, JL; Zaino, RJ | 1 |
| Bai, Y; Guo, Q; Li, C; Li, M; Wang, C; Yan, L; Zhang, H; Zhao, X | 1 |
| Kanao, H; Kondo, E; Matoda, M; Nomura, H; Sugiyama, Y; Takeshima, N; Tanigawa, T | 1 |
| Jeong, EG; Kim, ES; Seo, Y | 1 |
| Bai, Y; Gao, Y; Li, C; Li, M; Yan, L; Zhang, H; Zhang, L; Zhao, M; Zhao, X | 1 |
| Bi, Y; Chen, M; Jin, Y; Li, Y; Pan, L; Shan, Y | 1 |
| Hanaoka, H; Kiyokawa, T; Koshizaka, M; Mitsuhashi, A; Sato, Y; Shozu, M | 1 |
| Mayor, S | 1 |
| Anderson, GL; Aragaki, AK; Chen, C; Chlebowski, RT; Haque, R; Howard, BV; Manson, JE; Reed, SD; Rohan, TE; Runowicz, CD; Sarto, GE; Simon, MS; Thomson, CA; Wactawski-Wende, J | 1 |
| Honda, R; Katabuchi, H; Ohba, T; Saito, F; Suzuki, A; Tashiro, H; Yamaguchi, M | 1 |
| Behbakht, K; Guy, MS; Post, MD; Qamar, L; Sartorius, CA; Sheeder, J; Spillman, MA | 1 |
| Aoki, D; Banno, K; Hamatani, T; Hirasawa, A; Inoue, O; Kuji, N; Ogawa, S; Susumu, N; Takemoto, T; Tanaka, M; Yamagami, W | 1 |
| Chambers, SK; Guo, D; Liao, H; Park, JY; Wang, Y; Yi, X; Zhang, D; Zhang, Z; Zheng, W; Zheng, Y | 1 |
| Niu, YJ; Shi, HR; Xie, Y | 1 |
| Cândido, EB; Carneiro, MM; Carvalho-Macedo, AC; Lara, AC; Rocha, AL; Silva-Filho, AL; Vidigal, PV | 1 |
| Bae, HS; Jung, YW; Kim, DH; Kim, M; Kim, MK; Seong, SJ; Shim, JY; Yun, BS | 1 |
| Franco, EL; Gotlieb, WH; Greenwald, ZR; Huang, LN; Wissing, MD | 1 |
| Ai, ZH; Dai, M; Ge, QL; Jiang, SH; Li, J; Liu, F; Teng, YC; Wang, YH; Wu, QK; Xu, QY; Yang, XM; Zhang, ZG; Zhu, XL | 1 |
| Carballo, N; Chiva, L; García, JF; González-Cortijo, L; Gonzalez-Martín, A; Lapuente, F; Rojo, A | 1 |
| Kanemura, M; Ohmichi, M; Sasaki, H; Sekijima, T; Terai, Y; Yamashita, Y; Yasuda, M | 1 |
| Han, AR; Kim, DY; Kim, JH; Kim, YM; Kim, YT; Kwon, YS; Nam, JH | 1 |
| Hanprasertpong, J; Manusirivithaya, S; Tangjitgamol, S | 1 |
| Allison, M; Anderson, GL; Brzyski, R; Jackson, RD; Johnson, KC; Kuller, LH; Lane, DS; Langer, RD; Manson, JE; Ockene, J; Pettinger, M; Prentice, RL; Rossouw, JE; Sarto, G; Wactawski-Wende, J | 1 |
| Huo, Z; Lang, JH; Shen, K; Wu, M; Yang, JX; Yu, M | 1 |
| Hahn, HS; Hong, JS; Hong, SR; Kim, TJ; Kwon, YS; Lee, IH; Lee, KH; Lim, JY; Lim, KT; Mok, JE; Park, SJ; Shim, JU; Yoon, SG | 1 |
| Chen, Y; Lv, W; Mao, Y; Wan, X; Xie, X | 1 |
| Aoki, Y; Ishikawa, M; Miyazaki, K; Nagai, Y; Nakayama, K; Yaegashi, N | 1 |
| Ikeda, Y; Kawana, K; Kozuma, S; Nakagawa, S; Oda, K; Shoji, K; Takazawa, Y; Taketani, Y; Yasugi, T | 1 |
| Koyanagi, T; Kuromatsu, H; Miyabe, K; Nishio, S | 1 |
| Brockbank, E; Bryant, A; Gallagher, C; Kokka, F; Oram, D | 1 |
| Hu, Q; Ji, L; Liao, QP; Wang, YL; Xie, Y; Yu, L; Zhang, Y | 1 |
| Chen, X; Feng, Y; Gu, C; Liu, Y; Yin, L; Yu, Y; Zhang, Z; Zhao, F | 1 |
| Shah, MM; Wright, JD | 1 |
| Chung, HH; Kang, SB; Kim, JW; Kim, MK; Park, H; Seong, SJ; Yoon, BS | 1 |
| Bryant, A; Keep, SL; Kitchener, HC; Lilford, R; Martin-Hirsch, PP | 1 |
| Ai, Z; Teng, Y; Tong, J; Wang, J; Xu, Y | 1 |
| Chen, R; Hu, Q; Ji, L; Liao, QP; Wang, YL; Xie, Y; Yu, L; Zhang, Y | 1 |
| Chen, R; Hu, Q; Liao, Q; Xie, Y; Yu, L; Zhang, Y | 1 |
| Arteaga Gómez, AC; Castellanos Barroso, G; Márquez Acosta, G | 1 |
| Hong, SR; Kim, JW; Kim, MK; Lee, TS; Nam, BH; Seong, SJ; Suh, KS | 1 |
| Bae, DS; Kim, DY; Kim, JH; Kim, JW; Kim, KR; Kim, SM; Kim, TJ; Kim, YM; Kim, YT; Nam, JH; Park, JY; Seong, SJ | 1 |
| Bae, DS; Kim, JW; Kim, SM; Kim, TJ; Nam, JH; Park, JY; Seong, SJ | 1 |
| Bae, DS; Kim, DY; Kim, JH; Kim, JW; Kim, TJ; Kim, YM; Kim, YT; Lee, SH; Nam, JH; Park, JY; Seong, SJ | 1 |
| Anderson, GL; Beresford, SA; Howard, BV; Jackson, RD; Johnson, KC; Kooperberg, C; Kotchen, JM; LaCroix, AZ; Ockene, J; Prentice, RL; Rossouw, JE; Stefanick, ML | 1 |
| Pike, MC; Spicer, DV; Ursin, G | 1 |
| Mcdaniel, EB | 1 |
| Chandran, R | 1 |
| Kaunitz, AM | 2 |
| Brunnert, K; Kaufmann, M; Kreienberg, R; Loibl, S; Melchert, F; Mösch, R; Neises, M; Schermann, J; Seufert, R; Stiglmayer, R; Stosiek, U; von Minckwitz, G | 1 |
| Blok, LJ; Brinkmann, AO; Burger, CW; Helmerhorst, TJ; Huikeshoven, FJ; Kühne, LC; Smid-Koopman, E | 1 |
| Amezcua, CA; Boostanfar, R; Felix, JC; Roy, S; Stanczyk, FZ; Tourgeman, DE | 1 |
| Cline, JM; Isaksson, E; Sahlin, L; von Schoultz, B; Wang, H | 1 |
| Akino, F; Hamano, M; Hashimura, M; Kuramoto, H; Kuwata, T; Okayasu, I; Saegusa, M; Watanabe, J; Yoshida, T | 1 |
| Di Nezza, LA; Jobling, T; Salamonsen, LA | 1 |
| Blok, LJ; Burger, CW; De Gooyer, ME; De Ruiter, PE; Gielen, SC; Grootegoed, JA; Hanekamp, EE; Kloosterboer, HJ; Kühne, EC; Smid-Koopman, E | 1 |
| Fujita, K; Kase, H; Kurabayashi, T; Sugaya, S; Suzuki, M; Tanaka, K | 1 |
| Blok, LJ; Brinkmann, AO; Burger, CW; Chadha-Ajwani, S; de Ruiter, PE; Gielen, SC; Grootegoed, JA; Hanekamp, EE; Huikeshoven, FJ; Kühne, LC; Smid-Koopman, E | 1 |
| Anderson, GL; Barad, DH; Beresford, SA; Judd, HL; Kaunitz, AM; Liu, J; Lopez, AM; McNeeley, SG; Pettinger, M | 1 |
| Heinemann, V; Parhofer, K | 1 |
| Archer, DF; Leslie, S; Mirkin, S; Navarro, FJ | 1 |
| Aksu, T; Ayhan, A; Bozdag, G; Yarali, H | 1 |
| Herzog, TJ | 1 |
| Armstrong, DK; Brunetto, VL; Lee, RB; Lentz, SS; Sorosky, J; Whitney, CW; Zaino, RJ | 1 |
| Iwasaka, T; Kojima, K; Matsumoto, Y; Nakao, Y; Nomiyama, M; Yamasaki, F | 1 |
| Itoh, J; Kajiwara, H; Matsui, N; Miyamoto, T; Murakami, M; Osamura, RY; Shinozuka, T; Yasuda, M | 1 |
| Amezcua, C; Bahador, A; Burnett, AF | 1 |
| Merz, WE | 1 |
| Athayde, C; Coutinho, EM; Maia, H; Maltez, A; Studard, E | 1 |
| Boerstoel-Streefland, M; Hendricks, PT; Wierik, EJ | 1 |
| Beresford, SA; Doherty, JA; Hill, DA; Reed, SD; Voigt, LF; Weiss, NS | 1 |
| Hoshiai, H; Watanabe, Y | 1 |
| Izutsu, T; Sugiyama, T | 1 |
| Aoki, D; Banno, K; Nozawa, S; Susumu, N; Suzuki, A; Suzuki, N; Tamada, Y | 1 |
| Hiura, M; Nogawa, T; Oshita, T; Yokoyama, T | 1 |
| Butler-Manuel, S; Giannopoulos, T; Tailor, A | 1 |
| Blok, LJ; Burger, CW; Grootegoed, JA; Hanekamp, EE; Kühne, LM | 1 |
| Lian, Z; Mori, H; Niwa, K; Onogi, K; Tagami, K; Tamaya, T | 1 |
| Bamberger, AM; Briese, J; Erdmann, I; Götze, J; Nollau, P; Schulte, HM; Wagener, C | 1 |
| Frumovitz, M; Gershenson, DM | 1 |
| Carey, MS; Chambers, A; Fung-Kee-Fung, M; Gawlik, C; Oliver, T | 1 |
| Arai, T; Hamano, M; Jobo, T; Kamata, Y; Kawaguchi, M; Kuramoto, H; Nishimura, Y; Obokata, A; Watanabe, J | 1 |
| Fujiwara, T; Horie, K; Kugu, K; Minaguchi, T; Nakagawa, S; Nei, T; Osuga, Y; Takazawa, Y; Taketani, Y; Yano, T; Yasugi, T; Yoshikawa, H | 1 |
| Heikkinen, J; Timonen, U; Vaheri, R | 1 |
| Ito, K; Nagase, S; Yaegashi, N | 1 |
| Blok, LJ; Burger, CW; Hanifi-Moghaddam, P; Kloosterboer, HJ; Kuhne, EC; Nowzari, D; Ott, MC; Sijmons, B; van der Spek, P; van Ijcken, WF | 1 |
| Archer, DF; den Hollander, W; Ferenczy, A; Gallagher, JC; Helmond, FA; Hendrix, S; Rymer, J; Skouby, S; Stathopoulos, V | 1 |
| Chen, X; Feng, Y; Lu, X; Yu, Y; Zhao, S | 1 |
| Aydiner, A; Karagol, H; Kucucuk, S; Saip, P; Topuz, E; Uygun, K | 1 |
| Archer, DF; Mirkin, S | 1 |
| Filiaci, VJ; Leslie, KK; Singh, M; Zaino, RJ | 1 |
| Chen, XJ; Feng, YJ; Zhao, SJ | 1 |
| Fukunaga, M; Hatae, M; Hiura, M; Iwasaka, T; Kamura, T; Kodama, S; Konishi, I; Nakanishi, T; Saito, T; Saji, F; Sakamoto, A; Sasaki, H; Terakawa, N; Tsuda, H; Ushijima, K; Yaegashi, N; Yahata, H; Yasugi, T; Yoshikawa, H | 1 |
| Liu, X; Zhong, G; Zhu, G | 1 |
| Baltar Arias, R; Castro Ortiz, E; Fernández Salgado, E; Ibáñez Pinto, A; Ledo Barro, L; Vázquez Astray, E; Vázquez San Luis, J; Vázquez Vázquez, S | 1 |
| Chapman, W; Fyles, A; Gowing, K; Khokha, R; Li, M; Manoukian, AS; Tsao, MS; Wood, G | 1 |
| Harashima, S; Hirashima, Y; Ito, I; Kawaguchi, R; Takahashi, N; Takekuma, M; Yamada, Y | 1 |
| Iida, K; Ishibashi, M; Katagiri, A; Miyazaki, K; Nakayama, K; Nakayama, N; Shamima, Y | 1 |
| Fujimoto, J; Hori, M; Ichigo, S; Morishita, S; Tamaya, T | 3 |
| Isojima, S; Kawakita, M; Koyama, K; Nakata, Y; Ogasawara, T; Takemura, T; Tsuji, Y | 1 |
| Itoh, N; Mori, H; Morishita, S; Murase, T; Niwa, K; Tamaya, T; Tanaka, T | 1 |
| Baker, TR; Cornelison, TL; Driscoll, DL; Piver, MS | 1 |
| Hepp, H; Kimmig, R; Korell, M; Kürzl, R; Müller-Höcker, J; Strowitzki, T | 1 |
| Mizuuchi, H; Mori, Y; Okamura, N; Sato, K | 1 |
| Fujita, H; Ishizaki, T; Itoh, R; Okada, H; Yamamoto, T; Yasuda, J | 2 |
| Barbuto, DA; Judd, HL; Karlan, BY; Lagasse, LD; Leuchter, RS; McGonigle, KF | 1 |
| Gong, Y; Murphy, LC; Murphy, LJ | 2 |
| Itoh, M; Itoh, N; Morishita, S; Murase, T; Niwa, K; Shimokawa, K; Tamaya, T; Tanaka, T; Yokoyama, Y | 1 |
| Ces, J; Codesido, J; González, M; Macía, M; Novo, A; Quintana, S | 1 |
| Alkhalaf, M; Murphy, LC; Murphy, LJ | 1 |
| Lumbiganon, P | 1 |
| Burke, TW; Wolfson, AH | 1 |
| Jick, H; Jick, SS; Walker, AM | 1 |
| Acworth, P; Bourne, H; Haylock, BJ; Murrell, DS | 1 |
| Satyaswaroop, PG | 1 |
| Deerberg, F; Horn, DW; Schneider, MR; Vollmer, G | 1 |
| De Palo, G; Del Vecchio, M; Mangioni, C; Marubini, E; Periti, P | 1 |
| Delmore, JE; Horbelt, DV; Parmley, TH; Roberts, DK; Walker, N | 1 |
| Hackenberg, R; Schulz, KD | 1 |
| Berek, JS; Kim, YB; Martinez-Maza, O; Satyaswaroop, PG | 1 |
| Bamberger, AM; Bamberger, CM; Gellersen, B; Schulte, HM | 1 |
| Cullins, VE | 1 |
| Iacopino, F; Recchia, F; Sica, G | 1 |
| Rob, L | 1 |
| Hashimoto, M; Morishita, S; Takahashi, Y; Tamaya, T; Yokoyama, Y | 1 |
| Fujimoto, J; Hori, M; Ichigo, S; Tamaya, T | 1 |
| Comerci, JT; Fields, AL; Goldberg, GL; Runowicz, CD | 1 |
| Bukovsky, I; Hadas, E; Halperin, R; Maymon, R; Schneider, D | 1 |
| Lane, G; Martin-Hirsch, P; Salha, O; Sharma, V | 1 |
| Ernster, VL; Grady, D | 1 |
| Hyder, SM; Murthy, L; Stancel, GM | 1 |
| Bush, TL; Espeland, MA; Greendale, GA; Johnson, SR; Judd, HL; Legault, C; Trabal, J; Wasilauskas, CH | 1 |
| Fujimoto, J; Misao, R; Nakanishi, Y; Tamaya, T | 1 |
| Ikegami, H; Kurachi, H; Miyake, A; Morishige, K; Murata, Y; Nishio, Y; Ogura, K; Sakata, M; Yamaguchi, M | 1 |
| Aravantinos, G; Bafaloukos, D; Bakoyiannis, C; Katsifis, G; Kosmidis, P; Samonis, G; Skarlos, D | 1 |
| Anchezar Henry, JP; Gomez Rueda, N; Paniceres, G; Sardi, J; Vighi, S | 1 |
| Dgani, R; Fenig, E; Open, M; Shani, A; Vinker, S | 1 |
| Fujimoto, J; Hirose, R; Ichigo, S; Sakaguchi, H; Tamaya, T | 1 |
| Adelson, MD; Alvarez, RD; Brady, MF; Given, FT; Homesley, HD; Manetta, A; Soper, JT; Thigpen, JT | 1 |
| Fukunaga, K; Miyamoto, E; Miyazaki, K; Munir, I; Okamura, H | 1 |
| Jarvis, G; Kitchener, H; Lilford, R; Martin-Hirsch P, L | 1 |
| Satyaswaroop, PG; Tabibzadeh, S | 1 |
| Baumann, P; Deppe, G; Munkarah, A | 1 |
| Fujii, S; Kato, K; Konishi, I; Mitsushita, J; Toki, T | 1 |
| Araki, S; Koike, T; Ogawa, S; Ohwada, M; Sato, I; Shibahara, H; Suzuki, M | 1 |
| Fukunaga, M; Hataeg, M; Hiura, M; Iwasaka, T; Kaku, T; Kamura, T; Kodama, S; Kuwabara, Y; Kuzuya, K; Miyazaki, K; Nakano, H; Nishimura, T; Sakamoto, A; Sato, S; Tsuda, H; Yoshikawa, H | 1 |
| Chegini, N; Ma, C; Ripley, D; Tang, XM | 1 |
| Angelucci, C; Iacopino, F; Lama, G; Schinzari, G; Sica, G | 1 |
| Aisaka, K; Kaibara, M; Liang, SG; Okinaga, S; Ooka, F; Watanabe, T | 1 |
| Gibbons, WE; Thorneycroft, IH | 1 |
| Aoki, D; Nozawa, S; Susumu, N; Suzuki, N | 1 |
| Imai, M; Jobo, T; Kawaguchi, M; Kuramoto, H; Sato, R | 1 |
| Adamian, RT | 1 |
| Emons, G; Hinney, B; Huschmand, H; Krauss, T; Viereck, V | 1 |
| Fujiwara, H; Kosuge, S; Ohwada, M; Sato, I; Shibahara, H; Suzuki, M; Takamizawa, S; Usui, R | 1 |
| Jikihara, H; Matsumoto, K; Nishikawa, Y; Tanizawa, O; Terada, N; Terakawa, N; Yamamoto, R | 1 |
| Sumi, H; Tamaya, T; Yokoyama, Y | 1 |
| Campobasso, C; De Paoli, D; Giulini, D; Levato, F; Pansini, F; Serra, MM | 1 |
| Ishizaki, T; Itoh, R; Okada, H; Yamamoto, T | 1 |
| Pike, MC; Shoupe, D; Spicer, DV | 1 |
| Guillebaud, J; Szareswki, A | 1 |
33 review(s) available for medroxyprogesterone acetate and Cancer of Endometrium
| Article | Year |
|---|---|
Fertility-Sparing Approach in Women Affected by Stage I and Low-Grade Endometrial Carcinoma: An Updated Overview.
Topics: Adult; Endometrial Neoplasms; Female; Fertility; Fertility Preservation; Humans; Medroxyprogesterone Acetate; Myometrium; Neoplasm Staging; Progestins; Quality of Life | 2021 |
Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer or atypical hyperplasia: A systematic review and meta-analysis.
Topics: Abortion, Spontaneous; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Hyperplasia; Intrauterine Devices, Medicated; Levonorgestrel; Medroxyprogesterone Acetate; Precancerous Conditions; Pregnancy; Pregnancy Outcome | 2022 |
Fertility-Sparing Approach in Patients with Endometrioid Endometrial Cancer Grade 2 Stage IA (FIGO): A Qualitative Systematic Review.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Hormonal; Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Ki-67 Antigen; Levonorgestrel; Medroxyprogesterone Acetate; Megestrol Acetate; Neoplasm Recurrence, Local; NF-E2-Related Factor 2; Pregnancy; Progestins; Survivin | 2022 |
Curative Polyendocrine Therapy in a 21-year-Old Patient with Endometrial Carcinoma: Case Report and Review of the Literature.
Topics: Antineoplastic Agents, Hormonal; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Medroxyprogesterone Acetate; Retrospective Studies; Young Adult | 2023 |
Atypical polypoid adenomyoma follow-up and management: Systematic review of case reports and series and meta-analysis.
Topics: Adenomyoma; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Conservative Treatment; Curettage; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Hysteroscopy; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Pregnancy; Pregnancy Rate; Uterine Neoplasms | 2020 |
Hormone therapy for patients with advanced or recurrent endometrial cancer.
Topics: Endometrial Neoplasms; Female; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local; Neoplasm Staging; Progestins; Tamoxifen | 2014 |
Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.
Topics: Adult; Antineoplastic Agents, Hormonal; Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Hysterectomy; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local; Pregnancy; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Hysteroscopic resection in the management of early-stage endometrial cancer: report of 2 cases and review of the literature.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Protocols; Carcinoma; Dilatation and Curettage; Disease Management; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Hysteroscopy; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local; Neoplasm Staging; Pregnancy; Treatment Outcome | 2015 |
Sparing fertility in young patients with endometrial cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Female; Fertility; Humans; Medroxyprogesterone Acetate; Neoplasm Staging; Progestins; Treatment Outcome; Young Adult | 2008 |
Hormonal therapy in advanced or recurrent endometrial cancer.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Antineoplastic Agents, Hormonal; Disease-Free Survival; Drug Therapy, Combination; Endometrial Neoplasms; Female; Humans; Hydroxyprogesterones; Medroxyprogesterone Acetate; Megestrol; Neoplasm Recurrence, Local; Neoplasm Staging; Progestins | 2010 |
Adjuvant progestagens for endometrial cancer.
Topics: Antineoplastic Agents, Hormonal; Cause of Death; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Hydroxyprogesterones; Medroxyprogesterone Acetate; Progestins; Randomized Controlled Trials as Topic | 2011 |
[Recent outline of chemotherapy for uterine endometrial cancer].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Paclitaxel | 2004 |
[Hormone therapy for uterine corpus cancer--introduction].
Topics: 17 alpha-Hydroxyprogesterone Caproate; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Estrogens; Female; Gonadotropin-Releasing Hormone; Humans; Hydroxyprogesterones; Leuprolide; Medroxyprogesterone Acetate; Raloxifene Hydrochloride; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome | 2004 |
[Conservative hormonal therapy for endometrial cancer].
Topics: 17 alpha-Hydroxyprogesterone Caproate; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Female; Humans; Hydroxyprogesterones; Medroxyprogesterone Acetate; Megestrol Acetate; Neoplasm Recurrence, Local; Neoplasm Staging; Treatment Outcome | 2004 |
[Postoperative hormone (endocrine) therapy in endometrial carcinoma].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuvant; Drug Therapy, Combination; Endometrial Neoplasms; Estrogens; Female; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Medroxyprogesterone Acetate; Nitriles; Postoperative Care; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Fertility-sparing therapy for young women with endometrial cancer.
Topics: Adult; Age of Onset; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Female; Humans; Infertility, Female; Medroxyprogesterone Acetate; Megestrol Acetate; Patient Selection; Pregnancy; Pregnancy Outcome; Prognosis | 2006 |
Systematic review of systemic therapy for advanced or recurrent endometrial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic | 2006 |
[Endometrial carcinoma].
Topics: Antineoplastic Agents, Hormonal; Combined Modality Therapy; Diagnosis, Differential; Endometrial Neoplasms; Estrogens; Female; Humans; Hysterectomy; Medroxyprogesterone Acetate; Prognosis; Receptors, Estrogen | 2006 |
[Gastrointestinal bleeding of obscure origin caused by a metastatic endometrial adenocarcinoma. Response to hormonal therapy].
Topics: Aged; Antineoplastic Agents, Hormonal; Carcinoma, Endometrioid; Combined Modality Therapy; Endometrial Neoplasms; Female; Gastrointestinal Hemorrhage; Humans; Lymphatic Metastasis; Medroxyprogesterone Acetate; Pelvic Neoplasms; Peritoneal Neoplasms; Retroperitoneal Neoplasms; Tomography, X-Ray Computed; Umbilicus | 2007 |
Depot-medroxyprogesterone acetate (DMPA) and cancer of the endometrium and ovary.
Topics: Animals; Endometrial Neoplasms; Female; Humans; Macaca mulatta; Medroxyprogesterone Acetate; Ovarian Neoplasms; Thailand; United States | 1994 |
Limited endometrial carcinoma: adjuvant therapy.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Neoplasm Staging; Postoperative Care; Preoperative Care; Radiotherapy | 1994 |
Development of a preclinical model for hormonal therapy of human endometrial carcinomas.
Topics: Adenocarcinoma; Animals; Endometrial Neoplasms; Estradiol; Female; Humans; In Vitro Techniques; Medroxyprogesterone Acetate; Mice; Mice, Nude; Neoplasm Transplantation; Receptors, Estradiol; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured | 1993 |
Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen-like steroids.
Topics: Androgen Antagonists; Androgens; Androstane-3,17-diol; Androstenediol; Antineoplastic Agents, Hormonal; Apolipoproteins; Apolipoproteins D; Breast Neoplasms; Carcinoma; Carrier Proteins; Endometrial Neoplasms; Estrogen Antagonists; Female; Fibrocystic Breast Disease; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Medroxyprogesterone Acetate; Membrane Transport Proteins; Neoplasm Proteins; Pleural Effusion; Receptors, Androgen; Tumor Cells, Cultured | 1996 |
Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.
Topics: Breast Neoplasms; Case-Control Studies; Contraceptive Agents, Female; Delayed-Action Preparations; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Medroxyprogesterone Acetate; Risk Factors | 1996 |
Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate.
Topics: Anemia, Iron-Deficiency; Anemia, Sickle Cell; Contraceptive Agents, Female; Delayed-Action Preparations; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Pelvic Inflammatory Disease | 1996 |
Interferon and hormone sensitivity of endocrine-related tumors.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Hormones; Humans; Interferons; Male; Medroxyprogesterone Acetate; Prostatic Neoplasms; Tamoxifen; Tumor Cells, Cultured | 1996 |
Progestagens for endometrial cancer.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Hydroxyprogesterones; Medroxyprogesterone Acetate; Progestins | 2000 |
[Chemotherapy in metastatic or recurrent endometrial carcinoma].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Lymphatic Metastasis; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant | 2000 |
Endometrial carcinoma remaining after term pregnancy following conservative treatment with medroxyprogesterone acetate.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Neoplasm, Residual; Pregnancy; Pregnancy Complications, Neoplastic | 2000 |
Protecting the endometrium. Opposing the hyperplasia/malignancy potential of ERT.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Estrogen Replacement Therapy; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Progesterone; Progesterone Congeners; Risk Factors | 1999 |
[Hormonal therapy for endometrial adenocarcinoma].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic | 2001 |
[Hormonal therapy and chemotherapy of endometrial cancer].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Neoplasm Staging; Palliative Care | 2002 |
GnRH agonists as contraceptive agents: predicted significantly reduced risk of breast cancer.
Topics: Bone and Bones; Breast Neoplasms; Contraceptive Agents, Female; Endometrial Neoplasms; Estrogens, Conjugated (USP); Female; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Lipid Metabolism; Liver; Medroxyprogesterone; Medroxyprogesterone Acetate; Ovarian Neoplasms; Ovary; Risk Factors | 1991 |
30 trial(s) available for medroxyprogesterone acetate and Cancer of Endometrium
| Article | Year |
|---|---|
Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial).
Topics: Adult; Antineoplastic Agents, Hormonal; Clinical Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Follow-Up Studies; Humans; Hypoglycemic Agents; Medroxyprogesterone Acetate; Metformin; Proportional Hazards Models; Prospective Studies; Single-Blind Method; Treatment Outcome | 2020 |
While women await surgery for type I endometrial cancer, depot medroxyprogesterone acetate reduces tumor glandular cellularity.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Delayed-Action Preparations; Double-Blind Method; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Staging; Treatment Outcome; Waiting Lists | 2018 |
Six months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: a Korean Gynecologic-Oncology Group Study.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Hormonal; Biopsy, Needle; Carcinoma, Endometrioid; Dilatation and Curettage; Endometrial Neoplasms; Endometrium; Female; Fertility Preservation; Humans; Intrauterine Devices, Medicated; Levonorgestrel; Medroxyprogesterone Acetate; Prospective Studies | 2019 |
Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome.
Topics: Adult; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Colorectal Neoplasms, Hereditary Nonpolyposis; Contraceptives, Oral; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Medroxyprogesterone Acetate; Middle Aged; Mutation; Prognosis; Prospective Studies | 2013 |
Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.
Topics: Aged; Breast Neoplasms; Colorectal Neoplasms; Coronary Disease; Drug Therapy, Combination; Endometrial Neoplasms; Estrogens; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Hip Fractures; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Pulmonary Embolism; Quality of Life; Risk; Stroke; Treatment Outcome; United States | 2013 |
Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Humans; Immunohistochemistry; Medroxyprogesterone Acetate; Middle Aged | 2014 |
Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Female; Fertility; Fertility Preservation; Humans; Insulin Resistance; Medroxyprogesterone Acetate; Metformin; Neoplasm Recurrence, Local; Prospective Studies; Treatment Outcome; Young Adult | 2016 |
Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.
Topics: Aged; Double-Blind Method; Drug Administration Schedule; Endometrial Neoplasms; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Hysterectomy; Incidence; Kaplan-Meier Estimate; Medroxyprogesterone Acetate; Middle Aged; Odds Ratio; Postmenopause; United States; Women's Health | 2016 |
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.
Topics: Aged; Breast Neoplasms; Colorectal Neoplasms; Contraceptive Agents, Female; Coronary Disease; Endometrial Neoplasms; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Fractures, Bone; Humans; Incidence; Medroxyprogesterone Acetate; Menopause; Middle Aged; Postmenopause; Progestins; Pulmonary Embolism; Retrospective Studies; Risk Factors; Stroke; Survival Rate; Thrombosis; Time Factors; Washington | 2009 |
Conservative treatment with medroxyprogesterone acetate plus levonorgestrel intrauterine system for early-stage endometrial cancer in young women: pilot study.
Topics: Adult; Age Factors; Algorithms; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Endometrial Neoplasms; Feasibility Studies; Female; Humans; Infertility, Female; Intrauterine Devices, Medicated; Levonorgestrel; Medroxyprogesterone Acetate; Pilot Projects | 2011 |
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.
Topics: Aged; Breast Neoplasms; Clinical Trials Data Monitoring Committees; Colorectal Neoplasms; Coronary Disease; Endometrial Neoplasms; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fractures, Bone; Humans; Medroxyprogesterone Acetate; Middle Aged; Myocardial Infarction; Postmenopause; Progesterone Congeners; Proportional Hazards Models; Pulmonary Embolism; Risk; Stroke; Survival Analysis; Thrombosis; Treatment Outcome | 2002 |
Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer--a multicentre, open, controlled, prospectively randomised trial.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Tamoxifen; Treatment Outcome | 2002 |
Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.
Topics: Aged; Biopsy; Double-Blind Method; Endometrial Neoplasms; Endometrium; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Genital Neoplasms, Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Ovarian Neoplasms; Postmenopause; Proportional Hazards Models; Uterine Cervical Neoplasms; Vaginal Smears | 2003 |
[Risk and benefits of hormone replacement therapy by postmenopausal women. WHI-Study].
Topics: Aged; Breast Neoplasms; Colorectal Neoplasms; Coronary Disease; Endometrial Neoplasms; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fractures, Bone; Hormone Replacement Therapy; Humans; Incidence; Medroxyprogesterone Acetate; Middle Aged; Myocardial Infarction; Postmenopause; Progesterone Congeners; Proportional Hazards Models; Pulmonary Embolism; Risk Assessment; Stroke; Survival Analysis; Thrombosis; Treatment Outcome; United States; Women's Health | 2003 |
Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Tamoxifen | 2004 |
A 10-year follow-up of postmenopausal women on long-term continuous combined hormone replacement therapy: Update of safety and quality-of-life findings.
Topics: Breast Neoplasms; Dose-Response Relationship, Drug; Endometrial Neoplasms; Estradiol; Estrogens, Conjugated (USP); Female; Finland; Follow-Up Studies; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Quality of Life; Stroke; Treatment Outcome | 2006 |
Endometrial effects of tibolone.
Topics: Aged; Carcinoma; Cohort Studies; Double-Blind Method; Drug Combinations; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Norpregnenes; Pain; Uterine Hemorrhage | 2007 |
Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Endometrial Neoplasms; Estrogen Receptor alpha; Female; Humans; Immunohistochemistry; Medroxyprogesterone Acetate; Neoplasm Staging; Prospective Studies; Receptors, Progesterone; Tamoxifen; Treatment Outcome | 2007 |
Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women.
Topics: Adult; Aspirin; Carcinoma; Disease-Free Survival; Endometrial Neoplasms; Endometrium; Female; Fertility; Humans; Hyperplasia; Medroxyprogesterone Acetate; Pregnancy; Pregnancy Outcome; Prospective Studies; Treatment Outcome; Uterine Diseases | 2007 |
Cisplatin, adriamycin, etoposide, megestrol acetate versus melphalan, 5-fluorouracil, medroxyprogesterone acetate in the treatment of endometrial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Endometrial Neoplasms; Etoposide; Female; Fluorouracil; Humans; Medroxyprogesterone Acetate; Megestrol; Megestrol Acetate; Melphalan; Middle Aged; Prospective Studies; Survival Rate | 1995 |
Stage I endometrial carcinoma: the role of neoadjuvant progesterone therapy.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Prospective Studies; Survival Rate | 1993 |
Treatment of FIGO (1971) stage I endometrial carcinoma with intensive surgery, radiotherapy and hormonotherapy according to pathological prognostic groups. Long-term results of a randomised multicentre study.
Topics: Adult; Aged; Cause of Death; Combined Modality Therapy; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis | 1993 |
Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
Topics: Biopsy; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Estrogen Replacement Therapy; Estrogens; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Progesterone; Progesterone Congeners; Progestins | 1996 |
Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer.
Topics: Aged; Endometrial Neoplasms; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Progesterone Congeners; Risk Factors | 1997 |
Hormone replacement therapy and endometrial cancer: are current regimens safe?
Topics: Arteriosclerosis; Bone Density; Coronary Disease; Endometrial Neoplasms; Estrogen Replacement Therapy; Estrogens; Female; Humans; Medroxyprogesterone Acetate; Risk | 1997 |
Agreement in assessing endometrial pathology: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.
Topics: Biopsy; Cell Transformation, Neoplastic; Double-Blind Method; Endometrial Neoplasms; Endometrium; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Observer Variation; Progesterone Congeners; Sensitivity and Specificity | 1998 |
Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: A Hellenic cooperative oncology group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Drug Synergism; Endometrial Neoplasms; Female; Fluorouracil; Humans; Medroxyprogesterone Acetate; Methotrexate; Middle Aged; Prospective Studies; Treatment Outcome | 1999 |
Primary hormonal treatment for early endometrial carcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Biopsy, Needle; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Medroxyprogesterone Acetate; Neoplasm Staging; Treatment Outcome | 1998 |
Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Prognosis; Receptors, Progesterone; Recurrence; Survival Rate; Treatment Outcome | 1999 |
[Therapy of atypical hyperplasia and adenocarcinoma of the endometrium with the combination of progestins and anticoagulants].
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adenocarcinoma; Anticoagulants; Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Endometrial Neoplasms; Endometrium; Estrogen Antagonists; Female; Humans; Hydroxyprogesterones; Hyperplasia; Medroxyprogesterone Acetate; Neoplasm Staging; Progesterone Congeners; Treatment Outcome | 2001 |
160 other study(ies) available for medroxyprogesterone acetate and Cancer of Endometrium
| Article | Year |
|---|---|
Repurposing of antipsychotics perphenazine for the treatment of endometrial cancer.
Topics: Antineoplastic Agents; Antipsychotic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Repositioning; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Female; Humans; Molecular Structure; Perphenazine; Structure-Activity Relationship | 2020 |
Achievement of live birth after overcoming two gynecological malignancies treated with radical trachelectomy and medroxyprogesterone acetate therapy.
Topics: Adult; Antineoplastic Agents, Hormonal; Cesarean Section; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Live Birth; Medroxyprogesterone Acetate; Pregnancy; Trachelectomy; Uterine Cervical Neoplasms | 2021 |
Clinical Usefulness of Endometrial Cytology in Determining the Therapeutic Effect of Fertility Preserving Therapy.
Topics: Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Female; Fertility; Humans; Medroxyprogesterone Acetate; Retrospective Studies | 2022 |
NrCAM secreted by endometrial stromal cells enhances the progestin sensitivity of endometrial cancer cells through epigenetic modulation of PRB.
Topics: Animals; Cell Adhesion Molecules; Endometrial Neoplasms; Endometrium; Epigenesis, Genetic; Female; Humans; Medroxyprogesterone Acetate; Mice; Mice, Inbred BALB C; Mice, Nude; Mixed Function Oxygenases; Progestins; Proto-Oncogene Proteins; Receptors, Estrogen; Receptors, Progesterone; Stromal Cells | 2022 |
MPA alters metabolic phenotype of endometrial cancer-associated fibroblasts from obese women via IRS2 signaling.
Topics: Acetates; Cancer-Associated Fibroblasts; Endometrial Neoplasms; Female; Glucose; Humans; Insulin Receptor Substrate Proteins; Medroxyprogesterone Acetate; Mifepristone; Neoplasm Recurrence, Local; Obesity; Phenotype; Progesterone; Receptors, Progesterone; RNA, Messenger | 2022 |
Metformin attenuates the production and proliferative effects of prolactin induced by medroxyprogesterone acetate during fertility-sparing treatment for endometrial cancer.
Topics: Endometrial Neoplasms; Female; Humans; Insulin-Like Growth Factor Binding Protein 1; Medroxyprogesterone Acetate; Metformin; Progestins; Prolactin; RNA, Messenger | 2022 |
Aberrant upregulation of CDK1 contributes to medroxyprogesterone acetate (MPA) resistance in cancer-associated fibroblasts of the endometrium.
Topics: Cancer-Associated Fibroblasts; CDC2 Protein Kinase; Drug Resistance, Neoplasm; Endometrial Neoplasms; Endometrium; Female; Humans; Luciferases; Medroxyprogesterone Acetate; Mifepristone; Neoplasms; Receptors, Progesterone; RNA, Messenger; Up-Regulation | 2022 |
Obstetric outcomes after medroxyprogesterone acetate treatment for early stage endometrial cancer or atypical endometrial hyperplasia: a single hospital-based study.
Topics: Adult; Dilatation and Curettage; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Hospitals; Humans; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Staging; Obstetrics; Placenta Accreta; Pregnancy; Premature Birth; Retrospective Studies | 2023 |
Medroxyprogesterone acetate-resistant endometrial cancer cells are susceptible to ferroptosis inducers.
Topics: Endometrial Neoplasms; Female; Ferroptosis; Humans; Medroxyprogesterone Acetate; Reactive Oxygen Species; Sulfasalazine | 2023 |
MET Inhibits the Proliferation of EC Cells by Increasing MPA Sensitivity.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Metformin; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Proto-Oncogene Proteins c-akt; Receptors, Progesterone; TOR Serine-Threonine Kinases | 2023 |
Depot medroxyprogesterone acetate and endometrial cancer: A multicenter case-control study.
Topics: Case-Control Studies; Child, Preschool; Contraceptive Agents, Female; Delayed-Action Preparations; Endometrial Neoplasms; Endometrium; Female; Humans; Male; Medroxyprogesterone Acetate | 2023 |
Prognosis of patients with endometrial cancer or atypical endometrial hyperplasia after complete remission with fertility-sparing therapy.
Topics: Child; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local; Pregnancy; Prognosis; Retrospective Studies; Treatment Outcome | 2023 |
Genome-wide CRISPR screening reveals ADCK3 as a key regulator in sensitizing endometrial carcinoma cells to MPA therapy.
Topics: Cell Line, Tumor; Clustered Regularly Interspaced Short Palindromic Repeats; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Tumor Suppressor Protein p53 | 2023 |
Combination of hormonal-based therapy in endometrial cancer: ready for prime time.
Topics: Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate | 2023 |
Medroxyprogesterone acetate causes the alterations of endoplasmic reticulum related mRNAs and lncRNAs in endometrial cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Contraceptive Agents, Hormonal; Endometrial Neoplasms; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; Humans; Medroxyprogesterone Acetate; Membrane Proteins; Receptors, Progesterone; RNA, Long Noncoding; RNA, Messenger; Transcription Factor CHOP | 2019 |
Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Biomarkers; Biopsy; Disease Progression; DNA Mismatch Repair; DNA Polymerase II; Endometrial Neoplasms; Endometrium; Female; Fertility Preservation; Humans; Hysterectomy; Intrauterine Devices, Medicated; Medroxyprogesterone Acetate; Megestrol Acetate; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Receptors, Progesterone; Retrospective Studies; Tumor Suppressor Protein p53; Young Adult | 2021 |
Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Gonadotropin-Releasing Hormone; Humans; Levonorgestrel; Medroxyprogesterone Acetate; Megestrol Acetate; Neoplasm Recurrence, Local; Pregnancy; Pregnancy Outcome; Retreatment; Retrospective Studies; Young Adult | 2020 |
Continued medical treatment for persistent early endometrial cancer in young women.
Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Biopsy; Carcinoma, Endometrioid; Disease-Free Survival; Drug Administration Schedule; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Female; Fertility Preservation; Follow-Up Studies; Humans; Intrauterine Devices; Levonorgestrel; Magnetic Resonance Imaging; Medroxyprogesterone Acetate; Megestrol Acetate; Myometrium; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Prognosis; Retrospective Studies; Time Factors; Treatment Failure; Treatment Outcome; Ultrasonography | 2021 |
Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Ki-67 Antigen; Medroxyprogesterone Acetate; Middle Aged; Multivariate Analysis; Prognosis; Receptors, Androgen; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Treatment Outcome | 2017 |
[The Study of Decitabine Effect on the Endometrial Carcinoma Xenografted in Nude Mice.]
Topics: Animals; Apoptosis; Azacitidine; Cell Line, Tumor; Cisplatin; Decitabine; DNA Methylation; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Mice; Mice, Nude; Promoter Regions, Genetic; RNA, Messenger; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2016 |
Fertility Preserved Hysteroscopic Approach for the Treatment of Stage Ia Endometrioid Carcinoma.
Topics: Adult; Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Hysteroscopy; Medroxyprogesterone Acetate; Megestrol Acetate; Neoplasm Staging; Pregnancy; Retrospective Studies | 2017 |
Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Recurrence | 2018 |
Maintenance hormonal therapy after treatment with medroxyprogesterone acetate for patients with atypical polypoid adenomyoma.
Topics: Adenomyoma; Adult; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Kaplan-Meier Estimate; Maintenance Chemotherapy; Medroxyprogesterone Acetate; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Retrospective Studies; Risk Factors; Treatment Outcome | 2018 |
Administration of Cabergoline Contributes to Preserving Fertility in Young Hyperprolactinemic Patients With Endometrial Cancer Treated With Medroxyprogesterone Acetate.
Topics: Adult; Antineoplastic Agents, Hormonal; Cabergoline; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Hyperprolactinemia; Lectins, C-Type; Medroxyprogesterone Acetate; Retrospective Studies; Young Adult | 2018 |
Synergistic effect of metformin and medroxyprogesterone 17‑acetate on the development of endometrial cancer.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin E; Drug Synergism; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Medroxyprogesterone Acetate; Metformin | 2018 |
Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Curettage; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Recurrence, Local; Pregnancy | 2018 |
Conservative management of endometrial cancer: a survey amongst European clinicians.
Topics: Adult; Antineoplastic Agents, Hormonal; Conservative Treatment; Dilatation and Curettage; Endometrial Neoplasms; Endometrium; Europe; Female; Fertility Preservation; Humans; Hysteroscopy; Medroxyprogesterone Acetate; Myometrium; Neoplasm Recurrence, Local; Pregnancy; Progestins; Reproductive Techniques, Assisted; Retrospective Studies; Treatment Outcome | 2018 |
Roles of SIRT1/FoxO1/SREBP-1 in the development of progestin resistance in endometrial cancer.
Topics: Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Forkhead Box Protein O1; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Medroxyprogesterone Acetate; Progestins; Receptors, Progesterone; RNA, Messenger; Sirtuin 1; Sterol Regulatory Element Binding Protein 1 | 2018 |
Fertility-preserving treatment of stage IA, well-differentiated endometrial carcinoma in young women with hysteroscopic resection and high-dose progesterone therapy.
Topics: Adult; Antineoplastic Agents, Hormonal; Conservative Treatment; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Hysteroscopy; Medroxyprogesterone Acetate; Megestrol; Pregnancy | 2019 |
Coexistence of endometrial mesonephric-like adenocarcinoma and endometrioid carcinoma suggests a Müllerian duct lineage: a case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Carcinoma, Endometrioid; Cell Differentiation; Endometrial Neoplasms; Endometrium; Female; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Medroxyprogesterone Acetate; Mullerian Ducts; Retrospective Studies; Wolffian Ducts | 2019 |
Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Cell Growth Processes; Cell Line, Tumor; Down-Regulation; Endometrial Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Farnesol; Female; Gene Expression Regulation, Neoplastic; Humans; Medroxyprogesterone Acetate; Phosphorylation; ras Proteins; RNA, Messenger; Salicylates; Transcription, Genetic | 2013 |
Hormonal therapy for women with stage IA endometrial cancer of all grades.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Cohort Studies; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Neoplasm Recurrence, Local; Neoplasm Staging; Pregnancy; Pregnancy Outcome; Progestins; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Intrauterine Devices, Medicated; Levonorgestrel; Medroxyprogesterone Acetate; Prospective Studies; Remission Induction; Treatment Outcome | 2013 |
Successful use of dydrogesterone as maintenance therapy in recurrent endometrial stromal sarcoma: a case report.
Topics: Antineoplastic Agents, Hormonal; Drug Administration Schedule; Dydrogesterone; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Neoplasms, Hormone-Dependent; Progestins; Quality of Life; Sarcoma, Endometrial Stromal; Treatment Outcome | 2013 |
Long-term outcomes after progestogen treatment for early endometrial cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hysterectomy; Intrauterine Devices, Medicated; Levonorgestrel; Live Birth; Medroxyprogesterone Acetate; Pregnancy; Progestins; Time Factors; Young Adult | 2013 |
[Study of mechanism of medroxyprogesterone 17-acetate on the cancer stem cell-like properties of human endometrial cancer].
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Separation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Medroxyprogesterone Acetate; Neoplasm Proteins; Neoplastic Stem Cells; Tumor Stem Cell Assay | 2013 |
Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
Topics: Adult; Antineoplastic Agents, Hormonal; Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Hysterectomy; Medroxyprogesterone Acetate; Megestrol Acetate; Neoplasm Grading; Organ Sparing Treatments; Pregnancy; Pregnancy Outcome; Pregnancy Rate; Reproductive Techniques, Assisted; Retrospective Studies; Treatment Outcome | 2014 |
Outcome of fertility-sparing treatment with medroxyprogesterone acetate for atypical hyperplasia and endometrial carcinoma in young Japanese women.
Topics: Adult; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Forkhead Box Protein O1; Forkhead Transcription Factors; Humans; Immunohistochemistry; Japan; Medroxyprogesterone Acetate; Organ Sparing Treatments; Receptors, Progesterone; Treatment Outcome | 2014 |
Endometrial curettage in abnormal uterine bleeding and efficacy of progestins for control in cases of hyperplasia.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Curettage; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Treatment Outcome; Uterine Hemorrhage; Young Adult | 2014 |
Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
Topics: Antineoplastic Agents, Hormonal; Biomarkers; Cell Line, Tumor; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 6; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Immunohistochemistry; Medroxyprogesterone Acetate; Precancerous Conditions; Progestins; Treatment Outcome; Up-Regulation | 2015 |
Long-term outcomes of fertility-sparing treatment of atypical polypoid adenomyoma with medroxyprogesterone acetate.
Topics: Adenomyoma; Adult; Aged; Antineoplastic Agents, Hormonal; Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Fertility; Fertility Preservation; Humans; Hysterectomy; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pregnancy; Pregnancy Rate; Prognosis; Remission Induction; Retrospective Studies; Time Factors; Uterine Neoplasms | 2016 |
Cushing's syndrome with adrenal suppression and masked hyperandrogenism by high-dose medroxyprogesterone acetate for treatment of endometrial cancer in a young woman with polycystic ovarian syndrome.
Topics: Adult; Antineoplastic Agents, Hormonal; Cushing Syndrome; Endometrial Neoplasms; Female; Humans; Hyperandrogenism; Medroxyprogesterone Acetate; Polycystic Ovary Syndrome | 2015 |
SPAG9 May Be a Potential Prognostic Marker of Endometrial Hyperplasia and Grade 1 Endometrioid Adenocarcinoma Treated with Progestin.
Topics: Adaptor Proteins, Signal Transducing; Adult; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Blotting, Western; Carcinoma, Endometrioid; Cell Line, Tumor; Early Detection of Cancer; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Immunohistochemistry; Medroxyprogesterone Acetate; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction | 2016 |
Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; China; Disease-Free Survival; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility; Fertility Preservation; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Neoplasm Recurrence, Local; Obesity; Pregnancy; Progestins; Recurrence; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Continuous HRT with oestrogen plus progestogen is linked to reduced risk of endometrial cancer.
Topics: Endometrial Neoplasms; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate | 2015 |
Development of a mouse model for testing therapeutic agents: the anticancer effect of dienogest on endometrial neoplasms.
Topics: Animals; Antineoplastic Agents, Hormonal; Disease Models, Animal; Endometrial Neoplasms; Female; Medroxyprogesterone Acetate; Mice; Nandrolone; Progestins; Treatment Outcome | 2016 |
Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer.
Topics: AC133 Antigen; Adenocarcinoma; Adult; Aged; Antigens, CD; Antineoplastic Agents, Hormonal; Apoptosis; Cell Count; Cell Line, Tumor; Endometrial Neoplasms; Female; Glycoproteins; Humans; Medroxyprogesterone Acetate; Middle Aged; Neoplastic Stem Cells; Peptides; Receptors, Androgen; Receptors, Estrogen; Receptors, Progesterone | 2016 |
Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia.
Topics: Adult; Antineoplastic Agents, Hormonal; Carcinoma, Endometrioid; Endometrial Neoplasms; Endometrium; Female; Fertility Preservation; Humans; Infertility, Female; Logistic Models; Medroxyprogesterone Acetate; Multivariate Analysis; Odds Ratio; Pregnancy; Pregnancy Outcome; Recurrence; Retrospective Studies; Risk Factors | 2016 |
Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.
Topics: 20-Hydroxysteroid Dehydrogenases; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cell Line; Cell Proliferation; Drug Resistance, Neoplasm; Endometrial Neoplasms; Endometrium; Female; Humans; Medroxyprogesterone Acetate; Metformin; NF-E2-Related Factor 2; Progestins; Quassins; RNA Interference; RNA, Small Interfering | 2016 |
[Effect and regulation of metformin on endometrial carcinoma subline of progestin-resistance].
Topics: Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Medroxyprogesterone Acetate; Metformin; Progestins | 2016 |
Effect of letrozole in carcinogen-plus-estrogen-induced endometrial hyperplasia in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Carcinogenesis; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Estradiol; Ethylnitrosourea; Female; Letrozole; Medroxyprogesterone Acetate; Mice, Inbred BALB C; Nitriles; Progesterone; Reproducibility of Results; Time Factors; Treatment Outcome; Triazoles | 2016 |
Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Biopsy, Needle; Dilatation and Curettage; Endometrial Neoplasms; Endometrium; Female; Fertility Preservation; Humans; Intrauterine Devices; Levonorgestrel; Medroxyprogesterone Acetate; Progestins; Prospective Studies; Reproducibility of Results | 2017 |
Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer?
Topics: Adult; Antineoplastic Agents, Hormonal; Carcinoma, Endometrioid; Cause of Death; Cohort Studies; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Hysterectomy; Kaplan-Meier Estimate; Medroxyprogesterone; Medroxyprogesterone Acetate; Megestrol Acetate; Neoplasm Grading; Propensity Score; Proportional Hazards Models; SEER Program; Time Factors; United States | 2017 |
Cholesterol Synthetase DHCR24 Induced by Insulin Aggravates Cancer Invasion and Progesterone Resistance in Endometrial Carcinoma.
Topics: Aged; Cell Line, Tumor; Cell Movement; Endometrial Neoplasms; Endometrium; Enzyme Induction; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Insulin; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Invasiveness; Nerve Tissue Proteins; Oxidoreductases Acting on CH-CH Group Donors; Prognosis; Receptors, Progesterone; STAT3 Transcription Factor; Up-Regulation; Uterine Diseases | 2017 |
Successful pregnancy after conservative surgery for stage IA endometrial cancer in a young woman.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Carcinoma, Adenosquamous; Cesarean Section; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Fertility; Fiber Optic Technology; Humans; Hysteroscopy; Infant, Newborn; Live Birth; Medroxyprogesterone Acetate; Neoplasm Staging; Pregnancy | 2009 |
Pregnancy outcomes using assisted reproductive technology after fertility-preserving therapy in patients with endometrial adenocarcinoma or atypical complex hyperplasia.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Dilatation and Curettage; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Infertility, Female; Medroxyprogesterone Acetate; Megestrol Acetate; Pregnancy; Pregnancy Outcome; Reproductive Techniques, Assisted; Retrospective Studies | 2009 |
Fertility-sparing in endometrial cancer.
Topics: Adult; Algorithms; Biopsy; Cervix Uteri; Curettage; Endometrial Neoplasms; Female; Humans; Infertility, Female; Lymphatic Metastasis; MEDLINE; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Ploidies; Progesterone; Prognosis | 2009 |
Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Antineoplastic Agents, Hormonal; Cell Differentiation; Combined Modality Therapy; Endometrial Neoplasms; Endometrium; Female; Fertility; Follow-Up Studies; Humans; Hydroxyprogesterones; Hyperplasia; Infertility, Female; Medroxyprogesterone Acetate; Megestrol Acetate; Progestins; Remission Induction; Reproductive Techniques, Assisted; Retrospective Studies; Severity of Illness Index | 2009 |
Conservative treatment with progestin and pregnancy outcomes in endometrial cancer.
Topics: Adult; Algorithms; Antineoplastic Agents, Hormonal; Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Fertility; Follow-Up Studies; Gynecologic Surgical Procedures; Humans; Infertility, Female; Medroxyprogesterone Acetate; Megestrol Acetate; Pregnancy; Pregnancy Outcome; Progestins; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2009 |
Outcomes of conservative therapy for young women with early endometrial adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Female; Fertility; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Neoplasm Staging; Pregnancy; Pregnancy Outcome; Reproductive Techniques, Assisted; Retrospective Studies; Treatment Outcome | 2010 |
Prolonged long-term survival of low-grade endometrial stromal sarcoma patients with lung metastasis following treatment with medroxyprogesterone acetate.
Topics: Adult; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lung Neoplasms; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Staging; Ovariectomy; Retrospective Studies; Sarcoma, Endometrial Stromal; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Endometrial Neoplasms; Endometrial Stromal Tumors; Female; Humans; Medroxyprogesterone Acetate; Neoplasm Grading; Neoplasm Recurrence, Local; Nitriles; Triazoles | 2011 |
Progestogen treatment options for early endometrial cancer.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Curettage; Endometrial Neoplasms; Female; Humans; Hysterectomy; Intrauterine Devices, Medicated; Levonorgestrel; Medroxyprogesterone Acetate; Middle Aged; Neoplasm, Residual; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Retrospective Studies; Treatment Outcome; Young Adult | 2010 |
[Two cases of multidrug-resistant recurrent endometrial cancer successfully treated with medroxyprogesterone acetate (MPA)].
Topics: Aged; Antineoplastic Agents, Hormonal; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; Lung Neoplasms; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Staging; Recurrence; Remission Induction; Tomography, X-Ray Computed | 2010 |
Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Medroxyprogesterone Acetate; Metformin; Models, Biological; Receptors, Progesterone; Signal Transduction; TOR Serine-Threonine Kinases | 2011 |
Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Chromones; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Mice; Mice, Inbred BALB C; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptors, Progesterone; Signal Transduction | 2011 |
Management of endometrial cancer in young women.
Topics: Endometrial Neoplasms; Female; Humans; Hysterectomy; Infertility, Female; Medroxyprogesterone Acetate; Ovariectomy; Progestins; Risk Factors | 2011 |
Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endometrial Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Medroxyprogesterone Acetate; Mice; Mice, Inbred BALB C; Phosphorylation; Quinazolines; Receptors, Progesterone; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
5-aza-2'-deoxycytidine improves the sensitivity of endometrial cancer cells to progesterone therapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Apoptosis; Azacitidine; Carcinoma; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Decitabine; Drug Synergism; Drug Therapy, Combination; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Neoplasm Invasiveness; Receptors, Progesterone | 2012 |
Characterization of LHY-821, a novel moderately differentiated endometrial carcinoma cell line.
Topics: Animals; Cell Culture Techniques; Cell Line, Tumor; Endometrial Neoplasms; Female; Immunoblotting; Immunohistochemistry; Karyotyping; Medroxyprogesterone Acetate; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Receptors, Progesterone; Transplantation, Heterologous | 2012 |
[Conservative treatment of endometrial cancer as a way to preserve fertility. Five-year experience at Instituto Nacional de Perinatilogía Isidro Espinoza de los Reyes].
Topics: Adult; Antineoplastic Agents, Hormonal; Cohort Studies; Endometrial Neoplasms; Female; Fertility; Humans; Medroxyprogesterone Acetate; Pregnancy; Time Factors; Young Adult | 2012 |
Treatment with medroxyprogesterone acetate plus levonorgestrel-releasing intrauterine system for early-stage endometrial cancer in young women: single-arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2009).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Intrauterine Devices, Medicated; Levonorgestrel; Medroxyprogesterone Acetate; Multicenter Studies as Topic; Prospective Studies; Republic of Korea | 2012 |
Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002).
Topics: Administration, Oral; Adult; Antineoplastic Agents, Hormonal; Carcinoma, Endometrioid; Cohort Studies; Endometrial Neoplasms; Female; Fertility Preservation; Follow-Up Studies; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Pregnancy; Prognosis; Survival Rate; Young Adult | 2013 |
Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer.
Topics: Abortion, Spontaneous; Adult; Antineoplastic Agents, Hormonal; Carcinoma, Endometrioid; Disease-Free Survival; Endometrial Neoplasms; Female; Fertility Agents; Humans; Infant, Newborn; Infertility, Female; Medroxyprogesterone Acetate; Megestrol Acetate; Neoplasm Grading; Neoplasm Staging; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Rate; Pregnancy, Ectopic; Premature Birth; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin.
Topics: Adenocarcinoma; Adult; Endometrial Neoplasms; Female; Fertility Preservation; Follow-Up Studies; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Neoplasm Recurrence, Local; Progestins; Recurrence | 2013 |
Contraception and cancer prevention.
Topics: Americas; Biology; Breast Neoplasms; California; Case-Control Studies; Cell Biology; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Developed Countries; Disease; Endocrine System; Endometrial Neoplasms; Estrogens; Family Planning Services; Hormones; Lipids; Medroxyprogesterone Acetate; Neoplasms; North America; Ovarian Neoplasms; Physiology; Pilot Projects; Pituitary Hormone-Releasing Hormones; United States | 1994 |
Long-term use of hormonal contraceptive DMPA not linked to breast cancer.
Topics: Biology; Breast Neoplasms; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Disease; Endometrial Neoplasms; Family Planning Services; Medroxyprogesterone Acetate; Neoplasms; Risk Factors | 1995 |
Endometrial carcinoma survey in Thailand.
Topics: Asia; Asia, Southeastern; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Data Collection; Developing Countries; Disease; Endometrial Neoplasms; Family Planning Services; Incidence; Injections; Medroxyprogesterone Acetate; Neoplasms; Research; Research Design; Sampling Studies; Thailand | 1979 |
Injectable contraception.
Topics: Breast Neoplasms; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Disease; Endometrial Neoplasms; Family Planning Services; Infertility; Injections; International Agencies; Lactation; Medroxyprogesterone Acetate; Neoplasms; Organizations; Pregnancy; Uterine Cervical Neoplasms; Voluntary Health Agencies; Women | 1980 |
Statement on injectable contraception.
Topics: Animals, Laboratory; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Disease; Endometrial Neoplasms; Family Planning Services; Injections; International Agencies; Lactation; Medroxyprogesterone Acetate; Menstruation Disturbances; Neoplasms; Norethindrone; Organizations; Research; Steroids; Uterine Cervical Neoplasms | 1982 |
FDA gives final approval to Depo amid concerns over safety, cost and coercion.
Topics: Americas; Breast Neoplasms; Contraception; Contraception Behavior; Contraceptive Agents; Contraceptive Agents, Female; Developed Countries; Developing Countries; Disease; Economics; Endometrial Neoplasms; Family Planning Services; Government Agencies; International Agencies; Medroxyprogesterone Acetate; Neoplasms; North America; Organizations; Ovarian Neoplasms; Ovulation; Poverty; Social Class; Socioeconomic Factors; United Nations; United States; United States Public Health Service; Uterine Cervical Neoplasms; World Health Organization | 1992 |
Contraception and the big "C".
Topics: Biology; Breast Neoplasms; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptives, Oral; Contraceptives, Oral, Combined; Demography; Disease; Endocrine System; Endometrial Neoplasms; Estrogens; Family Planning Services; Hormones; Intrauterine Devices; Lactation; Medroxyprogesterone Acetate; Neoplasms; Ovarian Neoplasms; Ovulation; Physiology; Population; Population Dynamics; Time; Time Factors; Uterine Cervical Neoplasms | 1992 |
Injectable contraception: the USA perspective.
Topics: Americas; Breast Neoplasms; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Developed Countries; Disease; Endometrial Neoplasms; Evaluation Studies as Topic; Family Planning Services; Government Agencies; Health Services Accessibility; Injections; Medroxyprogesterone Acetate; Menstruation Disturbances; Neoplasms; Norethindrone; North America; Organizations; United States; United States Food and Drug Administration; United States Public Health Service | 1992 |
Distinct functional differences of human progesterone receptors A and B on gene expression and growth regulation in two endometrial carcinoma cell lines.
Topics: Cell Division; Endometrial Neoplasms; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Medroxyprogesterone Acetate; Progesterone; Progesterone Congeners; Promegestone; Receptors, Progesterone; Transfection; Tumor Cells, Cultured | 2003 |
Growth effects of raloxifene, estradiol, medroxy-progesterone acetate, and progesterone on human endometrial adenocarcinoma cells.
Topics: Adenocarcinoma; Cell Division; Endometrial Neoplasms; Estradiol; Estrogen Replacement Therapy; Female; Humans; Medroxyprogesterone Acetate; Progesterone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tumor Cells, Cultured | 2003 |
Effect of long-term treatment with steroid hormones or tamoxifen on the progesterone receptor and androgen receptor in the endometrium of ovariectomized cynomolgus macaques.
Topics: Animals; Endometrial Neoplasms; Endometrium; Estrogens, Conjugated (USP); Female; Gene Expression Regulation; Hormone Replacement Therapy; Macaca fascicularis; Medroxyprogesterone Acetate; Ovariectomy; Receptors, Androgen; Receptors, Progesterone; Tamoxifen | 2003 |
Up-regulation and nuclear localization of beta-catenin in endometrial carcinoma in response to progesterone therapy.
Topics: Active Transport, Cell Nucleus; Adult; Amino Acid Substitution; Antineoplastic Agents, Hormonal; beta Catenin; Biomarkers; Carcinoma, Endometrioid; Cell Differentiation; Cell Nucleus; Cytoskeletal Proteins; Endometrial Neoplasms; Endometrium; Female; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Hyperplasia; Luciferases; Medroxyprogesterone Acetate; Middle Aged; Mutation, Missense; Neoplasm Proteins; Point Mutation; Receptors, Progesterone; Recombinant Fusion Proteins; Trans-Activators; Transfection; Tumor Cells, Cultured | 2003 |
Progestin suppresses matrix metalloproteinase production in endometrial cancer.
Topics: Endometrial Neoplasms; Enzyme Activation; Epithelial Cells; Estradiol; Female; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Medroxyprogesterone Acetate; Progesterone Congeners; Stromal Cells; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured | 2003 |
Progestogenic effects of tibolone on human endometrial cancer cells.
Topics: Cell Division; Endometrial Neoplasms; Female; Fibronectins; Gene Expression Regulation; Humans; Insulin-Like Growth Factor Binding Protein 3; Medroxyprogesterone Acetate; Norpregnenes; Progesterone; Progestins; Receptors, Progesterone; Tumor Cells, Cultured | 2003 |
Endometrial abnormalities in infertile women.
Topics: Adult; Carcinoma; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Hysterectomy; Infertility, Female; Medroxyprogesterone Acetate; Pregnancy; Pregnancy Rate; Progesterone Congeners; Prognosis; Reproductive Techniques, Assisted; Retrospective Studies | 2003 |
Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer.
Topics: Adenocarcinoma; Cell Line, Tumor; Chondroitin Sulfate Proteoglycans; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Lectins, C-Type; Medroxyprogesterone Acetate; Neoplasm Invasiveness; Neoplasm Proteins; Receptors, Progesterone; Tenascin; Versicans | 2003 |
Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, and 17beta-estradiol on vascular endothelial growth factor isomers 121 and 165 in Ishikawa cells.
Topics: Adenocarcinoma; Endometrial Neoplasms; Endometrium; Estradiol; Female; Humans; Levonorgestrel; Medroxyprogesterone Acetate; Norethindrone; Prospective Studies; Protein Isoforms; Receptors, Progesterone; RNA, Messenger; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2004 |
A successful pregnancy after intracytoplasmic sperm injection and embryo transfer in a patient with endometrial cancer who was treated conservatively.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Cesarean Section; Embryo Transfer; Endometrial Neoplasms; Female; Humans; Magnetic Resonance Imaging; Medroxyprogesterone Acetate; Megestrol Acetate; Pregnancy; Pregnancy Outcome; Progesterone; Sperm Injections, Intracytoplasmic; Ultrasonography | 2004 |
What is the clinical value of adding tamoxifen to progestins in the treatment [correction for treament] of advanced or recurrent endometrial cancer?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Drug Synergism; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Neoplasm Recurrence, Local; Receptors, Progesterone; Tamoxifen | 2004 |
Successful pregnancies in 2 infertile patients with endometrial adenocarcinoma.
Topics: Adenocarcinoma; Adult; Biopsy, Needle; Combined Modality Therapy; Dilatation and Curettage; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Immunohistochemistry; Infertility, Female; Maternal Age; Medroxyprogesterone Acetate; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Reproductive Techniques, Assisted | 2004 |
Malignant transformation of atypical endometrial hyperplasia after progesterone therapy showing germ-cell tumor-like differentiation.
Topics: Adenocarcinoma; Adult; Alkaline Phosphatase; alpha-Fetoproteins; Biomarkers, Tumor; Cell Transformation, Neoplastic; Chorionic Gonadotropin; Endometrial Hyperplasia; Endometrial Neoplasms; Fatal Outcome; Female; Germinoma; GPI-Linked Proteins; Humans; Hysterectomy; Immunoenzyme Techniques; Isoenzymes; Loss of Heterozygosity; Medroxyprogesterone Acetate; Microsatellite Repeats | 2004 |
Anastrozole, an aromatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Nitriles; Obesity; Triazoles | 2004 |
[Hormone replacement therapy and the risk of developing breast cancer].
Topics: Breast Neoplasms; Cardiovascular Diseases; Climacteric; Endometrial Neoplasms; Estrogens, Conjugated (USP); Ethinyl Estradiol; Female; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Assessment | 2004 |
Effect of previous hormone replacement therapy on endometrial polyps during menopause.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Case-Control Studies; Endometrial Neoplasms; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Immunohistochemistry; Ki-67 Antigen; Medroxyprogesterone Acetate; Menopause; Middle Aged; Norethindrone; Norethindrone Acetate; Polyps; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Retrospective Studies | 2004 |
Clinical background of women prescribed tibolone or combined estrogen + progestogen therapies: a UK MediPlus study.
Topics: Breast Neoplasms; Drug Administration Schedule; Drug Therapy, Combination; Drug Utilization; Endometrial Neoplasms; Estradiol; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Norgestrel; Norpregnenes; Practice Patterns, Physicians'; Registries; Retrospective Studies; Risk Factors; United Kingdom | 2004 |
Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer.
Topics: Aged; Case-Control Studies; Contraceptive Agents, Female; Endometrial Neoplasms; Estrogen Replacement Therapy; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Progestins; Risk Assessment | 2004 |
Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Endometrial Neoplasms; Female; Humans; Intrauterine Devices; Levonorgestrel; Medroxyprogesterone Acetate | 2004 |
Progesterone receptor A and B expression and progestagen treatment in growth and spread of endometrial cancer cells in nude mice.
Topics: Animals; Cell Line; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Medroxyprogesterone Acetate; Mice; Mice, Nude; Neoplasm Invasiveness; Progestins; Receptors, Progesterone; Tumor Burden | 2004 |
Outcome of fertility-preserving treatment in young women with endometrial carcinomas.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Carcinoma; Carcinoma, Adenosquamous; Cohort Studies; Combined Modality Therapy; Dilatation and Curettage; Endometrial Neoplasms; Endometrium; Female; Follow-Up Studies; Humans; Infertility, Female; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Treatment Outcome | 2005 |
Stimulation of CEACAM1 expression by 12-O-tetradecanoylphorbol-13-acetate (TPA) and calcium ionophore A23187 in endometrial carcinoma cells.
Topics: Anti-Bacterial Agents; Antigens, CD; Calcimycin; Carcinoma; Cell Adhesion Molecules; Endometrial Neoplasms; Estradiol; Female; Hormone Antagonists; Humans; Interferon-gamma; Medroxyprogesterone Acetate; Mifepristone; Phorbol Esters; Protein Kinase C; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2006 |
Medroxyprogesterone acetate stimulates cdk inhibitors, p21 and p27, in endometrial carcinoma cells transfected with progesterone receptor-B cDNA.
Topics: Blotting, Western; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; DNA, Complementary; Endometrial Neoplasms; Female; Humans; Immunohistochemistry; Medroxyprogesterone Acetate; Receptors, Progesterone; Sampling Studies; Sensitivity and Specificity; Transfection; Tumor Cells, Cultured | 2006 |
Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium.
Topics: Adenocarcinoma; Administration, Oral; Adult; Combined Modality Therapy; Contraceptive Agents, Female; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Hysterectomy; Immunohistochemistry; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Staging; Phosphorylation; Pregnancy; Progestins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Receptors, Estrogen; Receptors, Progesterone; Time Factors; Treatment Outcome; Tumor Suppressor Protein p53 | 2007 |
The hormone replacement therapy drug tibolone acts very similar to medroxyprogesterone acetate in an estrogen-and progesterone-responsive endometrial cancer cell line.
Topics: Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; Estrogens; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Norpregnenes; Oligonucleotide Array Sequence Analysis; Progesterone; Transcription, Genetic | 2006 |
Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma.
Topics: Antineoplastic Agents, Hormonal; Cell Cycle; Cyclin D1; Drug Resistance, Neoplasm; Endometrial Neoplasms; ErbB Receptors; Estrogen Receptor alpha; Female; Humans; Immunohistochemistry; Medroxyprogesterone Acetate; Progestins; Receptors, Progesterone; RNA, Messenger; Signal Transduction | 2007 |
Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Doxorubicin; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Paclitaxel; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
Effects of tibolone and its metabolites on Angiopoietin-1, Tie-2 and tumor necrosis factor-alpha mRNA in Ishikawa cells. Implication for tibolone's effects on the endometrium.
Topics: Adenocarcinoma; Angiopoietin-1; Cell Line, Tumor; Contraceptive Agents, Female; Endometrial Neoplasms; Endometrium; Estradiol; Estrogen Receptor Modulators; Female; Humans; Medroxyprogesterone Acetate; Norpregnenes; Receptor, TIE-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Tumor Necrosis Factor-alpha | 2007 |
[Influence of long-term treatment with MPA on the biological character of endometrial carcinoma Ishikawa cell].
Topics: Antineoplastic Agents, Hormonal; Cell Cycle; Drug Resistance, Neoplasm; Endometrial Neoplasms; Endometrium; Female; Gene Expression; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Medroxyprogesterone Acetate; Neoplasm Invasiveness; Receptors, Progesterone; Tumor Cells, Cultured | 2007 |
Regulatory effect of estrogen, progestin and HB-EGF on the expression of HOXA10 gene in Ishikawa cells.
Topics: Cell Line, Tumor; Endometrial Neoplasms; Estradiol; Female; Genes, Homeobox; Heparin-binding EGF-like Growth Factor; Homeobox A10 Proteins; Homeodomain Proteins; Humans; Intercellular Signaling Peptides and Proteins; Medroxyprogesterone Acetate; RNA, Messenger | 2007 |
Neither ovariectomy nor progestin treatment prevents endometrial neoplasia in pten+/- mice.
Topics: Animals; Disease Models, Animal; Endometrial Neoplasms; Female; Genetic Predisposition to Disease; Immunohistochemistry; Male; Medroxyprogesterone Acetate; Mice; Mice, Inbred C57BL; Ovariectomy; PTEN Phosphohydrolase | 2008 |
A patient with stage 1a endometrial carcinoma in whom a solitary recurrent lesion was detected in the external iliac lymph node after MPA therapy.
Topics: Adult; Antineoplastic Agents, Hormonal; Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Humans; Lymphatic Metastasis; Medroxyprogesterone Acetate; Positron-Emission Tomography; Sentinel Lymph Node Biopsy | 2008 |
[Two cases of endometrial stromal sarcoma (ESS) in which survival was prolonged by administration of MPA].
Topics: Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Metastasis; Sarcoma, Endometrial Stromal | 2008 |
Estrogen activates migration potential of endometrial cancer cells through basement membrane.
Topics: Antineoplastic Agents, Hormonal; Basement Membrane; Cell Movement; Danazol; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Humans; Medroxyprogesterone Acetate; Neoplasm Invasiveness; Ovarian Neoplasms; Progesterone; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 1996 |
Progesterone treatment decreases sulfate carbohydrate antigen on endometrial carcinoma cells and inhibits the cell binding to laminin.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antigens, Tumor-Associated, Carbohydrate; Carbohydrate Sequence; Endometrial Neoplasms; Epitopes; Female; Humans; Immunohistochemistry; Laminin; Medroxyprogesterone Acetate; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Neoplasm Invasiveness; Neoplasm Metastasis; Sulfates; Tumor Cells, Cultured | 1995 |
Inhibitory effects of medroxyprogesterone acetate on mouse endometrial carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Carcinogens; Cocarcinogenesis; Disease Models, Animal; Dose-Response Relationship, Drug; Endometrial Neoplasms; Endometrium; Estradiol; Female; Medroxyprogesterone Acetate; Methylnitrosourea; Mice; Mice, Inbred ICR; Proliferating Cell Nuclear Antigen | 1995 |
Conservative treatment of endometrial cancer permitting subsequent triplet pregnancy.
Topics: Adult; Combined Modality Therapy; Curettage; Endometrial Neoplasms; Female; Gamete Intrafallopian Transfer; Humans; Medroxyprogesterone Acetate; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy, Multiple; Triplets | 1995 |
[A report of two endometrial cancer cases in that low-dose aspirin was effective for hypercoagulopathy caused by medroxyprogesterone acetate].
Topics: Adenocarcinoma; Adult; Aspirin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Thrombosis | 1995 |
[Treatment of recurrent uterine endometrial cancer in adjuvant therapy with medroxyprogesterone acetate (MPA) in addition of etoposide].
Topics: Adenocarcinoma; Administration, Oral; Aged; Drug Administration Schedule; Endometrial Neoplasms; Etoposide; Female; Humans; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local | 1995 |
[Estimation of medroxyprogesterone acetate (MPA) and etoposide against a human uterine endometrial cancer].
Topics: Animals; Cell Division; Drug Synergism; Endometrial Neoplasms; Etoposide; Female; Humans; Medroxyprogesterone Acetate; Mice; Mice, Nude; Subrenal Capsule Assay; Tetrazolium Salts; Thiazoles | 1994 |
Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy.
Topics: Aged; Aged, 80 and over; Biopsy; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endometrial Neoplasms; Estrogen Replacement Therapy; Estrogens; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Staging; Norethindrone; Norethindrone Acetate; Progestins; Retrospective Studies | 1994 |
Hormonal regulation of proliferation and transforming growth factors gene expression in human endometrial adenocarcinoma xenografts.
Topics: Adenocarcinoma; Animals; Blotting, Northern; Cell Division; Dexamethasone; Dihydrotestosterone; Endometrial Neoplasms; Estradiol; Female; Gene Expression Regulation, Neoplastic; Hormones; Humans; Medroxyprogesterone Acetate; Mice; Mice, Inbred BALB C; Tamoxifen; Transforming Growth Factor alpha; Transforming Growth Factor beta; Transplantation, Heterologous; Tumor Cells, Cultured | 1994 |
Successful pregnancy in a patient with endometrial carcinoma treated with medroxyprogesterone acetate.
Topics: Adenocarcinoma; Adult; Cesarean Section; Combined Modality Therapy; Dilatation and Curettage; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Placenta Previa; Pregnancy; Pregnancy Outcome | 1994 |
Progesterone challenge test for the assessment of endometrial pathology in asymptomatic menopausal women.
Topics: Biopsy; Endometrial Neoplasms; Endometrium; Female; Humans; Medroxyprogesterone Acetate; Menopause; Middle Aged; Predictive Value of Tests; Risk Factors; Sensitivity and Specificity | 1993 |
Enhanced c-jun activity alters responsiveness to medroxyprogesterone acetate in Ishikawa human endometrial carcinoma cells.
Topics: Carcinoma; Cell Division; Depression, Chemical; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Medroxyprogesterone Acetate; Neoplasm Proteins; Proto-Oncogene Proteins c-jun; Receptors, Glucocorticoid; Receptors, Progesterone; Recombinant Fusion Proteins; Transfection; Tumor Cells, Cultured | 1993 |
Estrogens, progesterone, and endometrial cancer.
Topics: Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endometrial Neoplasms; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Incidence; Medroxyprogesterone Acetate; Middle Aged; Risk Factors; Washington | 1993 |
The EnDA endometrial adenocarcinoma: an oestrogen-sensitive, metastasizing, in vivo tumour model of the rat.
Topics: Adenocarcinoma; Animals; Disease Models, Animal; Endometrial Neoplasms; Female; Medroxyprogesterone Acetate; Mice; Mice, Nude; Neoplasm Transplantation; Ovariectomy; Rats; Rats, Inbred Strains; Receptors, Estrogen; Tamoxifen; Transplantation, Isogeneic | 1993 |
The nuclear channel system in endometrial adenocarcinoma exposed to medroxyprogesterone acetate.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Cell Nucleus; Endometrial Neoplasms; Female; Glycogen; Humans; Medroxyprogesterone Acetate; Microscopy, Electron; Mitochondria; Postmenopause | 1996 |
Estrogen activates invasiveness of endometrial cancel cells to the interstitium.
Topics: Cell Movement; Collagen; Dose-Response Relationship, Drug; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Humans; Immunohistochemistry; Medroxyprogesterone Acetate; Neoplasm Invasiveness; Receptors, Estrogen; Tumor Cells, Cultured | 1995 |
Vascular endothelial growth factor expression is not regulated by estradiol or medroxyprogesterone acetate in endometrial carcinoma.
Topics: Actins; Animals; Carcinoma; Endometrial Neoplasms; Endothelial Growth Factors; Estradiol; Female; Humans; Lymphokines; Medroxyprogesterone Acetate; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1996 |
Progestins and danazol effect on cell-to-cell adhesion, and E-cadherin and alpha- and beta-catenin mRNA expressions.
Topics: Adenocarcinoma; alpha Catenin; beta Catenin; Cadherins; Cell Adhesion; Cell Aggregation; Cytoskeletal Proteins; Danazol; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Gene Expression Regulation, Neoplastic; Humans; Medroxyprogesterone Acetate; Progesterone; Progestins; RNA, Messenger; Trans-Activators; Tumor Cells, Cultured | 1996 |
Modulation of AP-1 activity by the human progesterone receptor in endometrial adenocarcinoma cells.
Topics: Adenocarcinoma; Animals; Base Sequence; Cell Line; Endometrial Neoplasms; Female; Haplorhini; Hormone Antagonists; Humans; Medroxyprogesterone Acetate; Mifepristone; Molecular Sequence Data; Promoter Regions, Genetic; Receptors, Estrogen; Receptors, Progesterone; Transcription Factor AP-1; Transfection; Tumor Cells, Cultured | 1996 |
[Hormonal therapy in the treatment of endometrial adenocarcinoma].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate | 1996 |
Immunohistochemical study of estradiol, epidermal growth factor, transforming growth factor alpha and epidermal growth factor receptor in endometrial neoplasia.
Topics: Adult; Aged; Aged, 80 and over; Endometrial Neoplasms; Epidermal Growth Factor; ErbB Receptors; Estradiol; Female; Frozen Sections; Humans; Immunohistochemistry; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Staging; Paraffin Embedding; Transforming Growth Factor alpha; Tumor Cells, Cultured | 1996 |
Sex steroids regulate the expression of plasminogen activator inhibitor-1 (PAI-1) and its mRNA in uterine endometrial cancer cell line Ishikawa.
Topics: 17-alpha-Hydroxyprogesterone; Adenocarcinoma; DNA, Neoplasm; Endometrial Neoplasms; Estradiol; Female; Gene Expression Regulation, Neoplastic; Gonadal Steroid Hormones; Humans; Medroxyprogesterone Acetate; Neoplasm Proteins; Neovascularization, Pathologic; Plasminogen Activator Inhibitor 1; Polymerase Chain Reaction; Progesterone; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Urokinase-Type Plasminogen Activator | 1996 |
Low levels of human decidua-associated protein 200 in uterine fluid reflect pathological conditions of the endometrium.
Topics: Adult; Aged; Body Fluids; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Immunoglobulins; Medroxyprogesterone Acetate; Menstruation; Middle Aged; Neoplasm Staging; Postmenopause; Pregnancy Proteins; Uterus | 1997 |
Endometrial carcinoma in a young patient with polycystic ovarian syndrome: first suspected at time of embryo transfer.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Embryo Transfer; Endometrial Neoplasms; Female; Fertilization in Vitro; Follow-Up Studies; Humans; Hysterectomy; Hysteroscopy; Medroxyprogesterone Acetate; Ovulation Induction; Polycystic Ovary Syndrome | 1997 |
Progestin regulation of vascular endothelial growth factor in human breast cancer cells.
Topics: Breast Neoplasms; Endometrial Neoplasms; Endothelial Growth Factors; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphokines; Medroxyprogesterone Acetate; Megestrol Acetate; Mifepristone; Neoplasm Proteins; Neovascularization, Pathologic; Norethindrone; Norethynodrel; Norgestrel; Progesterone; Progestins; Receptors, Progesterone; Stimulation, Chemical; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1998 |
Effect of medroxyprogesterone acetate on sex hormone-binding globulin mRNA expression in the human endometrial cancer cell line Ishikawa.
Topics: Antineoplastic Agents, Hormonal; Cell Differentiation; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Polymerase Chain Reaction; RNA, Messenger; Sex Hormone-Binding Globulin; Transcription, Genetic; Tumor Cells, Cultured | 1998 |
Messenger RNA differential display reverse-transcriptase-polymerase-chain-reaction analysis of a progestogen-suppressive gene in a human endometrial-cancer cell line.
Topics: Antineoplastic Agents, Hormonal; Blotting, Northern; Endometrial Neoplasms; Enoyl-CoA Hydratase; Female; Humans; Medroxyprogesterone Acetate; Neoplasm Proteins; Polymerase Chain Reaction; Progestins; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 1998 |
Conservative treatment of adenocarcinoma of the endometrium in young patients. Is it appropriate?
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Fallopian Tubes; Female; Humans; Hysterectomy; Medroxyprogesterone Acetate; Neoplasm Invasiveness; Ovariectomy; Parity; Polycystic Ovary Syndrome; Radiotherapy, Adjuvant | 1999 |
Progestins suppress estrogen-induced expression of vascular endothelial growth factor (VEGF) subtypes in uterine endometrial cancer cells.
Topics: 17-alpha-Hydroxyprogesterone; Blotting, Southern; Blotting, Western; Dose-Response Relationship, Drug; Endometrial Neoplasms; Endothelial Growth Factors; Estradiol; Female; Humans; Hydrocortisone; Immunoenzyme Techniques; Lymphokines; Medroxyprogesterone Acetate; Progesterone; Progestins; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrahydrocortisol; Time Factors; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1999 |
Mitogen-activated protein kinase activation and regulation of cyclooxygenase 2 expression by platelet-activating factor and hCG in human endometrial adenocarcinoma cell line HEC-1B.
Topics: Adenocarcinoma; Androstadienes; Antineoplastic Agents, Hormonal; Chorionic Gonadotropin; Cyclic AMP; Cyclooxygenase 2; Endometrial Neoplasms; Enzyme Activation; Enzyme Inhibitors; Estradiol; Female; Flavonoids; Humans; Isoenzymes; Isoquinolines; Medroxyprogesterone Acetate; Membrane Proteins; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Mitogens; Platelet Activating Factor; Prostaglandin-Endoperoxide Synthases; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides; Thionucleotides; Tumor Cells, Cultured; Wortmannin | 1999 |
Progestin regulation of human endometrial function.
Topics: Animals; Carcinoma; Crystallins; Embryo Implantation; Endometrial Neoplasms; Endometrium; Epithelial Cells; Female; Humans; Medroxyprogesterone Acetate; Mice; Mice, Nude; Progesterone; Progesterone Congeners; Progestins; Transplantation, Heterologous | 2000 |
Assisted reproductive technologies in conjunction with conservatively treated endometrial adenocarcinoma. A case report.
Topics: Adenocarcinoma; Adult; Curettage; Endometrial Neoplasms; Female; Gamete Intrafallopian Transfer; Humans; Infertility, Female; Medroxyprogesterone Acetate; Pregnancy; Pregnancy Outcome | 2001 |
Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility; Follow-Up Studies; Humans; Medroxyprogesterone Acetate; Pregnancy; Treatment Outcome | 2001 |
The expression and action of granulocyte macrophage-colony stimulating factor and its interaction with TGF-beta in endometrial carcinoma.
Topics: Antineoplastic Agents, Hormonal; Cell Division; Drug Interactions; Endometrial Neoplasms; Estradiol; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Medroxyprogesterone Acetate; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type II; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Cells, Cultured | 2001 |
Direct effects of GnRH agonists in human hormone-sensitive endometrial cells.
Topics: Antineoplastic Agents, Hormonal; Cell Division; Drug Synergism; Endometrial Neoplasms; Estrogen Receptor Modulators; Estrogens; Female; Gonadotropin-Releasing Hormone; Humans; Immunohistochemistry; Leuprolide; Medroxyprogesterone Acetate; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triptorelin Pamoate; Tumor Cells, Cultured | 2001 |
Effect of high-dose progestogen on hemostatic properties of blood in patients with endometrial cancer.
Topics: Adult; Aged; alpha-2-Antiplasmin; Antifibrinolytic Agents; Antineoplastic Agents, Hormonal; Antithrombin III; Blood Coagulation; Blood Coagulation Tests; Blood Viscosity; Combined Modality Therapy; Endometrial Neoplasms; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Fibrinolysin; Fibrinolysis; Hematocrit; Hemostasis; Humans; Hysterectomy; Medroxyprogesterone Acetate; Middle Aged; Partial Thromboplastin Time; Peptide Hydrolases; Platelet Count; Risk; Thrombophilia | 2001 |
Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Female; Fertility; Humans; Japan; Medroxyprogesterone Acetate; Prognosis; Treatment Outcome | 2001 |
Unsuspected uterine carcinosarcoma (heterologous) diagnosed following conservative therapies with medroxyprogesterone acetate for presumed early-stage endometrial carcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Carcinosarcoma; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Uterine Neoplasms | 2002 |
Inhibitory effect of medroxyprogesterone acetate on angiogenesis induced by human endometrial cancer.
Topics: Adenocarcinoma; Animals; Cornea; Endometrial Neoplasms; Female; Fibroblast Growth Factor 1; Humans; Medroxyprogesterone Acetate; Neoplasm Transplantation; Neovascularization, Pathologic; Rabbits; Transforming Growth Factor alpha | 1992 |
Effect of medroxyprogesterone acetate on immunohistochemical expression of estradiol in endometrial carcinoma.
Topics: Endometrial Neoplasms; Estradiol; Female; Humans; Interphase; Medroxyprogesterone Acetate | 1992 |
Combined use of progesterone challenge test and endometrium thickness evaluated by transvaginal ultrasonography in the preventive management of postmenopausal women.
Topics: Carcinoma; Endometrial Neoplasms; Endometrium; Female; Humans; Mass Screening; Medroxyprogesterone Acetate; Menopause; Middle Aged; Progesterone; Risk Factors; Ultrasonography | 1992 |
[Estimation of medroxyprogesterone acetate against a human endometrial tumor constituted from the established Ishikawa cancer cells by a subrenal capsule assay].
Topics: Animals; Antineoplastic Agents; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Mice; Mice, Nude; Neoplasm Transplantation; Subrenal Capsule Assay; Tumor Cells, Cultured | 1992 |
Regulation of transforming growth factor gene expression in human endometrial adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Division; Cell Line; Endometrial Neoplasms; Estrogen Antagonists; Female; Gene Expression Regulation, Neoplastic; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Oligonucleotides, Antisense; Steroids; Tamoxifen; Transforming Growth Factor alpha; Transforming Growth Factor beta | 1992 |
Safety of DMPA.
Topics: Age Factors; Antineoplastic Agents; Breast Neoplasms; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Risk Factors | 1991 |